Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019066548) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEART FAILURE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/066548 International Application No.: PCT/KR2018/011521
Publication Date: 04.04.2019 International Filing Date: 28.09.2018
IPC:
C12N 15/86 (2006.01) ,C12N 9/14 (2006.01) ,C07K 14/47 (2006.01) ,A61K 48/00 (2006.01) ,A61K 38/00 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79
Vectors or expression systems specially adapted for eukaryotic hosts
85
for animal cells
86
Viral vectors
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9
Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14
Hydrolases (3.)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
46
from vertebrates
47
from mammals
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
Applicants:
(주)벳바젠 BETHPHAGEN INC. [KR/KR]; 광주시 북구 첨단과기로 123, 203호 203-ho, 123, Cheomdangwagi-ro, Buk-gu, Gwangju 61005, KR
Inventors:
정동탁 JEONG, Dongtak; US
곽태환 KWAK, Tae Hwan; KR
박우진 PARK, Woo Jin; KR
Agent:
제일특허법인(유) FIRSTLAW P.C.; 서울시 서초구 마방로 60 60 Mabang-Ro, Seocho-Ku Seoul 06775, KR
Priority Data:
10-2017-012744229.09.2017KR
Title (EN) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEART FAILURE
(FR) COMPOSITION PHARMACEUTIQUE POUR LA PRÉVENTION OU LE TRAITEMENT D'UNE INSUFFISANCE CARDIAQUE
(KO) 심부전의 예방 또는 치료용 약학적 조성물
Abstract:
(EN) The present invention relates to a pharmaceutical composition for prevention and treatment of heart failure. Specifically, the present invention relates to a gene construct comprising a polynucleotide coding for SERCA2a protein or a fragment thereof and a polynucleotide coding for CCN5 protein or a fragment thereof, and a pharmaceutical composition comprising the same construct as an effective ingredient for preventing or treating heart failure. A pharmaceutical composition for prevention and treatment of heart failure according to the present invention is used in a method for co-expression of SERCA2a protein and CCN5 protein. Designed to exert a synergistic therapeutic effect through SERCA2a protein's function of preventing the loss of cardiomyocytes and increasing the activity of cardiomyocytes and CCN5 protein's function of suppressing the fibrosis of heart cells and tissues, the pharmaceutical composition can be useful for preventing or treating heart failure, which is a complex disorder induced by various etiological factors.
(FR) La présente invention concerne une composition pharmaceutique pour la prévention et le traitement d'une insuffisance cardiaque. En particulier, la présente invention concerne une construction génique comprenant un polynucléotide codant pour la protéine SERCA2a ou un fragment de celle-ci, et un polynucléotide codant pour la protéine CCN5 ou un fragment de celle-ci, et une composition pharmaceutique comprenant la même construction en tant que principe actif pour prévenir ou traiter une insuffisance cardiaque. Une composition pharmaceutique pour la prévention et le traitement d'une insuffisance cardiaque selon la présente invention est utilisée dans un procédé de co-expression de la protéine SERCA2a et de la protéine CCN5. Conçue pour exercer un effet thérapeutique synergique par l'intermédiaire de la fonction de la protéine SERCA2a consistant à prévenir la perte de cardiomyocytes et à augmenter l'activité des cardiomyocytes, et de la fonction de la protéine CCN5 consistant à inhiber la fibrose des cellules et tissus cardiaques, la composition pharmaceutique peut être utile pour prévenir ou traiter une insuffisance cardiaque, qui est un trouble complexe induit par divers facteurs étiologiques.
(KO) 본 발명은 심부전의 예방 및 치료용 약학적 조성물에 관한 것이다. 구체적으로, 본 발명은 SERCA2a 단백질 또는 이의 단편을 암호화하는 뉴클레오타이드와 CCN5 단백질 또는 이의 단편을 암호화하는 뉴클레오타이드를 포함하는 유전자 컨스트럭트 및 이를 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명의 심부전 예방 및 치료용 약학적 조성물은 SERCA2a 단백질과 CCN5 단백질을 동시에 발현시키는 방법이다. SERCA2a 단백질에 의한 심근세포의 소멸방지 및 활성 증가뿐만 아니라, CCN5 단백질에 의한 심장 세포 및 조직의 섬유화 억제를 통해 상승적 치료효과를 발휘하여 다양한 병인에 의해 유도된 복잡한 질환인 심부전을 예방 또는 치료하는데 유용하게 사용될 수 있다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)